drugset / Trial / NCT02431364
Trial of Safety and Tolerability of Oral Verdinexor (KPT-335) in Healthy Adults
RandomizedSequentialDouble-blindBasic science
Summary
This is a randomized, double-blind, sequential, dose-escalation, Phase 1 trial to evaluate the safety and tolerability of verdinexor. Verdinexor or placebo will be given on Days 1 and 3 to healthy adult participants.
Timeline
- Start
- 2015-05-26
- Primary completion
- 2015-10-01
- Completion
- 2015-10-01
Outcome
Outcome not reported
Stopped: “Administrative reason”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Verdinexor | Small molecule | 5 mg | Oral |
| Subject | Verdinexor | Small molecule | 10 mg | Oral |
| Subject | Verdinexor | Small molecule | 20 mg | Oral |
| Subject | Verdinexor | Small molecule | 40 mg | Oral |
Indications
No indication recorded.